share_log

CbdMD Unveils ATRx Labs Premium Mushroom Line at GNC, Expanding CbdMD's Natural Wellness Solutions

CbdMD Unveils ATRx Labs Premium Mushroom Line at GNC, Expanding CbdMD's Natural Wellness Solutions

cbdMD 在 GNC 推出 ATrX Labs 優質蘑菇系列,擴展了 cbdMD 的自然健康解決方案
newsfile ·  05/24 22:03

Charlotte, North Carolina--(Newsfile Corp. - May 24, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company") is thrilled to announce the launch of its highly anticipated ATRx Labs Premium Mushroom Line, available exclusively at GNC stores nationwide. Crafted with a blend of powerful mushroom extracts, derived from the fruiting bodies of the mushrooms and complimented by clinically studied ingredients, these supplements are designed to cater to a wide array of health needs for consumers across the nation.

cbdMD公司(紐約交易所美國板塊:YCBD; 紐約交易所美國板塊: YCBD-PA)非常高興地宣佈,其備受期待的ATRx Labs高檔蘑菇系列已經推出,目前只在全國GNC商店提供。基於蘑菇實體的強效提取物和臨床研究成分的完美配方,這些補品旨在爲全國的消費者提供各種健康需求的解決方案。

As consumers increasingly seek natural alternatives to support their well-being, cbdMD has answered the call with its new ATRx Labs Premium Mushroom Line. Harnessing the power of nature's powerhouse functional mushrooms, each product in the line is meticulously formulated to address specific health needs, from supporting healthy cognitive and immune function to caffeine-free focus and healthy weight management.

隨着消費者越來越尋求天然替代品來支持其健康,cbdMD的新ATRx Labs高檔蘑菇系列應運而生。借鑑自然功能蘑菇的巨大力量,系列中的每一種產品都經過精心調配,旨在應對特定的健康需求,從支持健康認知和免疫功能、到無咖啡因的焦點以及健康的重量管理。

"We are excited to introduce our exclusive Premium Mushroom Line at GNC, a trusted destination for quality health and wellness products," said Ronan Kennedy, CEO and CFO at cbdMD. "Our team has worked tirelessly to develop these cutting-edge supplements, leveraging the growing body of science around functional mushrooms to deliver effective and natural solutions for our customers."

“我們很高興能在GNC推出我們的獨家高檔蘑菇系列,這是一個值得信賴的高品質健康和保健產品目的地,”cbdMD的CEO和CFO Ronan Kennedy說。“我們的團隊爲開發這些領先的補品而不懈努力,利用日益增長的蘑菇功能科學成果,爲我們的客戶提供有效的天然解決方案。”

The Premium Mushroom Line includes four distinct products, each designed to offer unique benefits:

高檔蘑菇系列包括四個獨特的產品,每個產品旨在提供獨特的益處:

  1. Power: Energy & Stamina Platinum Mushroom Capsules - Engineered for those seeking a natural energy boost, these capsules combine Cordyceps Militaris and Green Tea extract (EGCG) with EnXtra, a clinically studied caffeine-free solution to enhance alertness and focus.
  2. Nootropic Mind: Memory & Cognition Platinum Mushroom Capsules - Tailored for cognitive enhancement, this product incorporates Lion's Mane, Huperzine A and a clinically studied Bacopa Moneri extract, Bacomind, to support memory, learning, attention, and overall brain health.
  3. Weight Management: Digestion & Microbiome Platinum Mushroom Capsules - A powerful blend of Turkey Tail and Capsimax, an ingredient which was clinically studied to naturally manage appetite, support digestion, increase energy expenditure, and aid in effective weight management.
  4. Everyday Immune: Wellness & Support Platinum Mushroom Capsules - Combining Chaga, Turkey Tail, and Cordyceps, this product is formulated to support the immune system, reducing fatigue, and promoting overall wellness.
  1. Power: 能源和耐力鉑金蘑菇膠囊爲那些尋求天然能量提升的人量身定製,這些膠囊將Cordyceps Militaris和綠茶提取物(EGCG)與EnXtra結合使用,後者是一種經過臨床研究的不含咖啡因的溶液,可增強警覺性和專注力。
  2. Nootropic Mind: 記憶和認知鉑金蘑菇膠囊專爲認知增強而設計的這款產品,結合了獅鬃、秦艽鹼和經過臨床研究的巴科帕蒙尼提取物,巴科美,以支持記憶、學習、注意力和整體大腦健康。
  3. Weight Management: 消化和微生物鉑金蘑菇膠囊由火花傘和Capsimax強效混合物組成,後者經過臨床研究,可以自然地控制食慾、支持消化、增加能量消耗並幫助有效管理體重。
  4. Everyday Immune: 健康和支持鉑金蘑菇膠囊結合查加、火花傘和蟲草,此產品的配方旨在支持免疫系統,減少疲勞,促進整體健康。

This exclusive range of products are currently only available at GNC stores nationwide, offering customers convenient access to these innovative health supplements.

這個獨家系列的產品目前只在全國GNC商店銷售,爲顧客提供這些創新的健康補品的便利渠道。

"We believe that everyone deserves access to premium supplements that are safe, effective, and backed by science," continued Kennedy. "Our partnership with GNC helps us make this vision a reality. To address the growing consumer demand, cbdMD developed ATRx Labs which is focused on cutting-edge health and wellness products without cannabinoids or CBD."

“我們認爲每個人都應該有權訪問經過安全、有效和科學支持的高檔補品,”肯尼迪繼續說。“我們和GNC的合作有助於實現這一願景。爲了滿足日益增長的消費者需求,cbdMD開發了ATRx Labs(專注於沒有大麻素或CBD的前沿健康和保健產品)。”

As both companies look forward to the positive impact this collaboration will have on consumers nationwide, they remain dedicated to setting new standards in the health and nutrition industry.

隨着兩家公司期待這種合作對全國消費者的積極影響,他們一直致力於在健康與營養行業中樹立新的標準。

For more information about ATRx Labs, visit atrxlabs.com. Engage on social at @ATRx_Labs.

欲獲取更多有關ATRx Labs的信息,請訪問atrxlabs.com。在社交媒體上參與@ATRx_Labs。

About cbdMD, Inc.:
cbdMD, Inc. is one of the leading and most highly trusted and most recognized Cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, including NSF Certified for Sport products, as well as a wide array of Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids, and a growing collection of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures and chews in varying strengths, and our ATRx Labs brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit , , or ATRxLabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retailers nationwide that carry cbdMD's products.

關於cbdMD公司:
THC-free是指使用經過驗證的科學分析方法檢測下限以下的水平。1本公司已經開始準備其截至2024年7月5日的計劃提交給紐交所美國。如果紐交所美國接受計劃,公司將能夠在計劃期間繼續上市,並將受到紐交所美國工作人員的持續定期審查。如果未提交計劃,未被紐交所美國接受計劃或被接受但未能在2025年12月5日之前符合持續上市標準,或計劃期間未能與計劃一致取得進展,公司將按照紐交所美國公司指南中規定的除牌程序受到處理。1如需了解有關cbdMD公司的CBD油和全光譜產品以及其他品牌,請訪問cbdmd.com、pawcbd.com或atrxlabs。com,在Instagram和Facebook上關注cbdMD,或訪問遍佈全國的成千上萬的零售商之一,這些零售商銷售cbdMD的產品。

Forward-Looking Statements:
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to our collaboration with GNC, federal and state regulation of dietary supplement products, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2023as filed with the Securities and Exchange Commission (the "SEC") and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

前瞻性聲明:
本新聞稿包含一些基於目前預期並涉及一定風險和不確定性的前瞻性陳述,這些前瞻性陳述屬於1995年美國私人證券訴訟改革法所涉及的某些風險和不確定性範疇。這些前瞻性陳述可使用“應該”、“可能”、“打算”、“預計”、“相信”、“估計”、“項目”、“預測”、“預期”、“計劃”和“提出”的字眼來識別。這些前瞻性陳述並非未來業績的保證,存在風險、不確定性和其他因素,其中一些因素超出了我們的控制並難以預測。敬請您仔細檢查和考慮任何警示性聲明,包括但不限於我們與GNC的合作、聯邦和州對膳食補品產品的監管以及其他披露,包括cbdMD公司提交給證券交易委員會(SEC)的截至2023年9月30日結束的財政年度的10-K表格的標題下的聲明“風險因素”以及我們對SEC的其他提交。所有前瞻性陳述均涉及重大風險和不確定性,這些風險和不確定性可能導致實際結果與前瞻性陳述中的結果明顯不同,其中許多風險和不確定因素通常超出了cbdMD公司的控制範圍,並且難以預測。cbdMD公司不承擔任何更新前瞻性陳述的責任,除非法律要求這樣做。出現在我們網站和社交媒體平台(包括但不限於Instagram和Facebook)上的信息不屬於本新聞稿的一部分。

Contact Information:
cbdMD, Inc.
Ronan Kennedy, Interim CEO & CFO
+1 (704) 445-3064
IR@cbdmd.com

聯繫方式:
cbdMD, Inc.
Ronan Kennedy,臨時CEO和CFO
+1 (704) 445-3064
IR@cbdmd.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論